3 citations
,
June 1983 in “Archives of Dermatology” This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.
October 2025 in “Frontiers in Pharmacology” This review explores the immunopharmacological potential of A. lappa for inflammatory musculoskeletal disorders (IMSDs) but reports no new clinical results, emphasizing the need for standardized research methodologies.
24 citations
,
April 2007 in “European Journal of Pharmaceutics and Biopharmaceutics” This study found that artocarpin delivered via alginate/chitosan microparticles effectively suppressed the growth of hamster flank organs compared to artocarpin in solution form, without significant systemic effects.
1 citations
,
November 1988 in “Veterinary Record” In this case study, oral folic acid therapy resulted in noticeable improvement and eventual recovery from hair loss and skin issues in a three-week-old Charolais calf.
25 citations
,
September 2014 in “Biological Research” This study found that arctiin, a compound from Arctium lappa, demonstrated protective effects against oxidative stress-induced dysfunction in human hair dermal papilla cells, suggesting potential therapeutic use for alopecia.
This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.
39 citations
,
May 2006 in “Molecular Plant-Microbe Interactions” This study suggests that fusaric acid at nontoxic concentrations may activate signal transduction in plants which could aid in the plant-defense responses against Fusarium spp.
January 2023 in “Pharmaceutics” In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.
November 2015 in “Ankara Medical Journal” This study concluded that weekly 5 mg folate supplementation is adequate for preventing methotrexate toxicity in rheumatoid arthritis patients, with no observed advantage to higher daily dosing after six months.
January 2026 in “Frontiers in Public Health” This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.
August 2015 in “Dermatología Argentina” This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.
2 citations
,
March 2019 in “PubMed” This case report describes successful treatment of folliculitis decalvans in a 41-year-old woman using oral fusidic acid, leading to clinical improvement and no recurrences after six months.
10 citations
,
March 2016 in “Journal of The American Academy of Dermatology” This review discusses the potential usefulness and safety profile of oral antiandrogens for treating frontal fibrosing alopecia, noting possible benefits but acknowledges that finasteride's efficacy remains uncertain.
This article discusses the broad traditional uses and potential pharmaceutical applications of burdock, recommending the development of new products but reporting no experimental findings.
4 citations
,
October 2013 in “Botanics Targets and Therapy” In this animal study, a herbal preparation demonstrated moderate anti-inflammatory and immunomodulating properties, suggesting its potential usefulness for preventing and treating alopecia.
6 citations
,
November 2020 in “JAAD Case Reports” This study identified overlapping genetic susceptibility loci in both alopecia areata and inflammatory bowel disease, specifically with Crohn's disease and ulcerative colitis.
4 citations
,
May 2018 in “European journal of dermatology/EJD. European journal of dermatology” Fumaric acid esters might help treat alopecia areata, but more research is needed.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.
5 citations
,
December 1964 in “Australasian journal of dermatology” This article discusses congenital atrichia and presents no new clinical findings.
114 citations
,
December 1951 in “Archives of Dermatology” This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.
24 citations
,
September 2015 in “JAAD case reports” This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.
14 citations
,
August 2009 in “Cancer epidemiology” This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.
June 2026 in “Frontiers in Medicine” This study evaluated the 308-nm excimer laser as an adjuvant treatment for frontal fibrosing alopecia and found it may stabilize hairline recession and improve erythema and perifollicular hyperkeratosis, with transient erythema as the only reported adverse effect.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
2 citations
,
November 2021 in “ACG Case Reports Journal” This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.
102 citations
,
April 2014 in “International Journal of Dermatology” This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.